Next 10 |
2024-04-16 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-03 08:15:04 ET Evercore ISI analyst issues OUTPERFORM recommendation for JSPR on April 3, 2024 06:38AM ET. JSPR was trading at $26.2 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recomme...
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (C...
2024-03-28 16:03:29 ET More on Jasper Therapeutics Jasper Therapeutics to effect 1-for-10 reverse stock split Seeking Alpha’s Quant Rating on Jasper Therapeutics Historical earnings data for Jasper Therapeutics Financial information for Jasper Therapeu...
REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (C...
REDWOOD CITY, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and ...
Three additional patients with Fanconi Anemia treated with briquilimab prior to stem cell transplant All six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated REDWOOD CITY, Calif.,...
2024-03-06 12:53:30 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Jasper Therapeutics (NASDAQ: JSPR ) just reported results for the fourth quarter of 2023. Jasper Therapeutics reported earnings per share of -$1.50. This was above the ana...
REDWOOD CITY, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell driven diseases such as chronic spontaneous urticaria (CSU) and ...
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CS...
News, Short Squeeze, Breakout and More Instantly...
Jasper Therapeutics Inc. Company Name:
JSPR Stock Symbol:
NASDAQ Market:
2024-04-16 18:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-03 08:15:04 ET Evercore ISI analyst issues OUTPERFORM recommendation for JSPR on April 3, 2024 06:38AM ET. JSPR was trading at $26.2 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy recomme...
REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on de...